Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy

Mark C. Markowski; Pedro Isaacsson Velho; Mario A. Eisenberger; Martin G. Pomper; Kenneth J. Pienta; Michael A. Gorin; Emmanuel S. Antonarakis; Samuel R. Denmeade; Steven P. Rowe

doi:10.2967/jnumed.120.259226

Detection of Early Progression with ¹⁸F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy

Mark C. Markowski, Pedro Isaacsson Velho, Mario A. Eisenberger, Martin G. Pomper, Kenneth J. Pienta, Michael A. Gorin, Emmanuel S. Antonarakis, Samuel R. Denmeade, Steven P. Rowe

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT. Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL-avid lesion. Results: Three of 6 (50%) patients had progression on 18F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on 18F-DCFPyL PET/CT. For the 3 patients who did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.

Original language	English (US)
Pages (from-to)	1270-1273
Number of pages	4
Journal	Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume	62
Issue number	9
DOIs	https://doi.org/10.2967/jnumed.120.259226
State	Published - Sep 1 2021

Keywords

PSMA
early progression
testosterone

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2967/jnumed.120.259226

Cite this

Markowski, M. C., Velho, P. I., Eisenberger, M. A., Pomper, M. G., Pienta, K. J., Gorin, M. A., Antonarakis, E. S., Denmeade, S. R., & Rowe, S. P. (2021). Detection of Early Progression with ¹⁸F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(9), 1270-1273. https://doi.org/10.2967/jnumed.120.259226

Detection of Early Progression with ¹⁸F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. / Markowski, Mark C.; Velho, Pedro Isaacsson; Eisenberger, Mario A. et al.

In: Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 62, No. 9, 01.09.2021, p. 1270-1273.

Research output: Contribution to journal › Article › peer-review

Markowski, MC, Velho, PI, Eisenberger, MA , Pomper, MG , Pienta, KJ, Gorin, MA, Antonarakis, ES , Denmeade, SR & Rowe, SP 2021, 'Detection of Early Progression with ¹⁸F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 62, no. 9, pp. 1270-1273. https://doi.org/10.2967/jnumed.120.259226

@article{70d50317be464b86903b9cce3c2ad73c,

title = "Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy",

abstract = "Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT. Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL-avid lesion. Results: Three of 6 (50%) patients had progression on 18F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on 18F-DCFPyL PET/CT. For the 3 patients who did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.",

keywords = "PSMA, early progression, testosterone",

author = "Markowski, {Mark C.} and Velho, {Pedro Isaacsson} and Eisenberger, {Mario A.} and Pomper, {Martin G.} and Pienta, {Kenneth J.} and Gorin, {Michael A.} and Antonarakis, {Emmanuel S.} and Denmeade, {Samuel R.} and Rowe, {Steven P.}",

note = "Publisher Copyright: {\textcopyright} 2021 by the Society of Nuclear Medicine and Molecular Imaging.",

year = "2021",

month = sep,

day = "1",

doi = "10.2967/jnumed.120.259226",

language = "English (US)",

volume = "62",

pages = "1270--1273",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "9",

}

TY - JOUR

T1 - Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy

AU - Markowski, Mark C.

AU - Velho, Pedro Isaacsson

AU - Eisenberger, Mario A.

AU - Pomper, Martin G.

AU - Pienta, Kenneth J.

AU - Gorin, Michael A.

AU - Antonarakis, Emmanuel S.

AU - Denmeade, Samuel R.

AU - Rowe, Steven P.

PY - 2021/9/1

Y1 - 2021/9/1

N2 - Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT. Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL-avid lesion. Results: Three of 6 (50%) patients had progression on 18F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on 18F-DCFPyL PET/CT. For the 3 patients who did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.

AB - Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT. Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL-avid lesion. Results: Three of 6 (50%) patients had progression on 18F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on 18F-DCFPyL PET/CT. For the 3 patients who did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.

KW - PSMA

KW - early progression

KW - testosterone

UR - http://www.scopus.com/inward/record.url?scp=85117623297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117623297&partnerID=8YFLogxK

U2 - 10.2967/jnumed.120.259226

DO - 10.2967/jnumed.120.259226

M3 - Article

C2 - 33452039

AN - SCOPUS:85117623297

SN - 0161-5505

VL - 62

SP - 1270

EP - 1273

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 9

ER -